and obesity. 6 Based on a previous study, the therapeutic approaches have not been successful in the limitation of disease progression in CRF. 7 Hemodialysis (HD) is a well-established and long-standing lifesaving treatment for CFR patients. 8 Dialysis is the filtration of blood through a semipermeable membrane under certain electrochemical concentration gradient. 9 The main purpose of HD is to maintain molecular homeostasis of the extracellular environment, which involves removal of waste products including uremic solutes, and excess sodium and water. 10 Hemodiafiltration (HDF) is the process of diluting whole blood with a physiologic electrolyte solution followed by ultrafiltration across a membrane to convectively remove solutes and excess water.
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Hemoperfusion (HP) is defined as a therapy that is proficient in purifying blood and eliminating the immune mediator. 12 HDF and HD are distinguished by the pore size in the area of fiber since the hollow fiber of the dialyzers is made by semipermeable membrane. 13 CD40
is a constituent of the receptor superfamily of tumor necrosis factor and is expressed upon antigen-presenting cells, such as dendritic cells, B cells, and monocytes as well as many nonimmune cells and a range of tumors. 14, 15 The interaction of CD40 with CD40L can lead to the formation of a prothrombotic and proinflammatory molecule, and CD62P, as p-selectin and a constituent of the platelet α-granule membrane, is expressed on the platelet surface. 16 CD80, as a constituent of immunoglobulin supergene family, is expressed upon dendritic cells 17 and can facilitate tumor immunity by preventing the immune suppression of programmed death ligand 1. 18 The simultaneous blockade of CD80 causes complete inhibition of majority of T cell-mediated responses, either by preventing T-cell activation altogether, or by sequentially inhibiting T cell-dependent recruitment of effector immune responses. 19 P10 is a viroporin that can generate the process of cell fusion. 20 Due to shortage of evidence by studies focusing on the three HD methods in the treatment of CRF and their effects on the protein expression of CD40, CD80, CD62P, and P10, we conducted this study to examine the efficacy of these HD methods on the expression of CD40, CD80, CD62P, and P10 in CRF patients, the clinical outcomes of HDF and the correlation with the presence of complications following treatment.
| MATERIAL S AND ME THODS

| Ethical statements
This study was performed with the approval of the Ethics Committee of the First Affiliated Hospital of Zhengzhou University, with signed informal consents by all patients.
| Study subjects
A total of 240 CRF patients between March 2012 and January 2014
in The First Affiliated Hospital of Zhengzhou University (Zhengzhou, Henan, China) that met the diagnostic criteria for CRF in the clinical practice guideline of renal anemia were selected as the study subjects. 21 According to different methods of HD, patients were divided into HD group (n = 
| Treatment regimens
All patients from each group underwent HD therapy, using the 4008S dialysis machine (Fresenius, Taunusstein-Neuhof, Germany).
Patients in the HD group were treated with cellulose triacetate dialyzer (150G; Nipro, Tokyo, Japan) three times a week for 6 months, Co., Ltd., Zhuhai, China) and underwent 1-time HP and 5-times HD every 2 weeks with the blood flow adjusted to 220-250 mL/min, for 6 months. Prior to the treatment, the body weight and blood pressure of the patient were measured and recorded, the dialyzer was properly connected with the pipeline and was operated to preheat and self-test, and the prepared heparin saline was employed for preflushing and circulation in order to exhaust the air in the dialyzer and the pipeline. Thereafter, the vascular access was established first through an arteriovenous puncture, which was followed by an intravenous injection of the first dose of heparin (JianFu Medical Technology Co., Ltd., Guangzhou, China). Afterward, the blood pump started; the blood from the arterial end was derived from the body and returned to the body through the dialyzer. During the hemodialysis period, different medications and symptomatic treatments, including decompression, the correction for anemia, and ion disorders, were applied depending on the patients' condition.
| Measurement of indexes
Serum phosphorus, serum calcium (SCa), blood urea nitrogen (BUN), serum creatinine (Scr), plasma albumin (ALB), hemoglobin (HGB), triglyceride (TG), parathyroid hormone (PTH), beta 2-macroglobulin (β2-MG) and the patients' dry weight, white blood cell (WBC), and platelet count were recorded for the patients in all groups before and after 6 months of hemodialysis. The improvement of patients' subjective feelings (including symptoms as fatigue, somnus, appetite, osteodynia, and uremic pruritus) was evaluated through a questionnaire.
Self-control method and SF-36 were adopted in order to investigate 
| Determination of the expression of CD40, CD80, CD62, and P10
Before and after HD, 5 mL of venous blood was extracted from the patients in each group, followed by the addition of 2% ethylenediaminetetraacetic acid-2Na anticoagulant (3 V Biotechnology
Co., Ltd., Weifang, China) and 0.7% NaCl in order to prevent blood coagulation. Mononuclear cells were isolated using a Ficoll-Paque Afterward, the tubes were centrifuged at 2500 g/min and flushed by 400 μL of PBS after discarding the supernatant. Finally, the protein expression was detected using a flow cytometer. All the aforementioned antibodies were purchased from BD Biosciences.
22,23
| Statistical analysis
All data were analyzed by SPSS20.0 (IBM, Armonk, NY, USA).
Measurement data were expressed by mean ±standard deviation.
The experimental data were analyzed with variance analysis of repeated measurements. The data in each group were processed with test of normality and test of homogeneity of variance using ShapiroWilk and Levene methods separately. When the data reached normal distribution or homogeneity of variance, Bonferroni test was conducted, if the Kruskal-Wallis failed. Enumeration data were expressed by ratio or percentage and compared using chi-square test, with P < 0.05 and P < 0.01 implying to significant and exceedingly significant differences, respectively. 
| RE SULTS
| Comparisons of baseline characteristics of all enrolled study subjects
| Metabolites are very effectively cleared by HD treatment
No changes were observed in BUN ( Figure 1A ) and Ca ( Figure 1D 
| The symptoms related to CRF are predominantly improved in patients after HD therapy
The subjective feelings such as fatigue, poor sleep, poor appetite, osteodynia, uremic pruritus, and neuropsychiatric disorders were either significantly reduced or completely abated and the dry weight increased significantly in CRF patients after 6 months of therapy, which was statistically different from the recorded weight before treatment (all P < 0.05; Table 2 ). In comparison with the score before HD, the score of living quality of CRF patients in the HD, HDF, and HP groups noticeably improved (all P < 0.05). Following dialysis, the score of living quality of the HDF and HP groups was obviously higher than that of the HD group (all P < 0.05), and the score of living quality of the HP group was higher than that of the HDF group (P < 0.05; Figure 2 ).
These results suggested that the associated symptoms of CRF patients predominantly improved after HD therapy and that HD therapy in the treatment of CRF has achieved certain therapeutic efficacy.
| The changes in the expression of CD40, CD80, CD62P, and P10 before and after different methods of HD therapy
As shown in Figure 3 , the expression of CD40 and CD80 in monocytes in the blood samples of healthy controls was higher than that of CRF patients before treatment, and it remarkably increased in mononuclear cells in peripheral blood in patients after different HD therapies (all P < 0.05). The expression of CD40 and CD80 after HD therapy in the HDF and HP groups was higher than that of the HD group (all P < 0.05), while the expression of the HP group was higher than the HDF group (P < 0.05). The expression of CD62P and P10 in platelets in the blood samples of healthy controls was lower than that of CRF patients before treatment, and it decreased obviously in peripheral blood platelets in patients following the different regimens of HD therapies (all P < 0.05). The expression of CD62P and P10 after HD therapy in the HDF and HP groups was lower than that of the HD group (all P < 0.05) and that in the HP group was lower than the HDF group (P < 0.05).
| Decreased expression of CD62P and P10 and high expression of CD40 and CD80 are correlated with better therapeutic efficacy
According to the efficacy assessment, patients from each group were subdivided into effective group and ineffective group. There were 50 patients in the effective group and 30 patients in the ineffective group of the HD group, 56 patients in the effective group and 24 patients in the ineffective group of the HDF group and 64 patients in the effective group and 16 patients in the ineffective group of the HP group. A decrease in the expression of CD62P and P10 was observed in the effective group with a high expression in the ineffective group, while CD40 and CD80 showed high expression in the effective group and low expression in the ineffective group in all three groups (all P < 0.05; Figure 4 ). These results highly indicated that the therapeutic efficacy was better in CRF patients with low expression of CD62P and P10 and high expression of CD40 and CD80 after HD therapy.
| Decreased expression of CD62P and P10 and increased expression of CD40 and CD80 are correlated with lower chances of complications after HD therapy
The relationship between the expression of CD40, CD80, CD62P, P10, and the arising complications of HD therapy was assessed. The results showed that the incidence of these complications reached 45.0% in the patients in the HD group, with 12 cases of hypertension, four cases of heart failure, eight cases of cardiac arrhythmia, four cases of angina pectoris, four cases of itchy skin, and four cases of muscle spasm. In the HDF group, there were four cases of hypertension, zero case of heart failure, four cases of cardiac arrhythmia, zero case of angina pectoris, four cases of itchy skin, and zero case of muscle spasm, with the incidence up to 15.0% after HD therapy. In the HP group, there were four cases of hypertension, zero case of heart failure, zero case of cardiac arrhythmia, zero case of angina pectoris, four cases of itchy skin, and zero case of muscle spasm, with the incidence up to 10.0% after HD therapy. The complication incidence in the HDF and HP groups was lower than that in the HD group, while the complication incidence in the HP group was much lower than that in the HDF group (all P < 0.05). On the basis of the analysis on the relationship between the existing complications among the three groups, significant differences were observed in the occurrence and probability of the complications of hypertension, heart failure, arrhythmia, angina pectoris, and muscle spasm among the three groups (Table 3) . Patients in all groups were later divided into complicated group and uncomplicated group according to the complications after treatment, with the complicated group presenting with a high expression of CD62P
and P10 while a lower expression was observed in the uncomplicated group (all P < 0.05). The expressions of CD40 and CD80 were shown to have decreased in the complicated group, while they increased in the uncomplicated group (all P < 0.05; Figure 5 ). Generally, these results revealed that that after HD therapy, a decrease in the expression of CD62P and P10 with a high expression of CD40 and CD80 was evident, along with lowered incidence of complications in CRF patients.
| D ISCUSS I ON
Chronic renal failure or CKD is a global epidemic, with clinical manifestations including deregulation of salt and water homeostasis, changes in endocrine functions and renal detoxification capacity, which has a deleterious impact on the overall survival of patients. 27 ,28 HD has made a remarkable achievement in prolonging F I G U R E 2 Quality of life improved in patients following HD therapy; A-G, comparisons of parameters such as the overall health status, somatic pain, somatic role, social function, energy, psychological health, and emotional role in each group before and after 6 mo of hemodialysis; HD, hemodialysis; HDF, hemodiafiltration; HP, hemoperfusion; *, P < 0.05 vs before treatment; 
29,30
Kalantar-Zadeh et al reported that a low level of ALB in CKD patients is associated with malnutrition and higher serum albumin is indicative of a poor prognosis in patients on dialysis. 32 HD therapy, combined with blood perfusion, has been reported to effectively Furthermore, the present study also discovered significant change in the aforementioned indexes following HDF and HP treatment compared with HD treatment. A previous study showed that HDF is successful in reducing the β2-MG level and protein carbonyl and in eliminating uremic toxins, thereby improving the adequacy of dialysis in CRF and the quality of life of dialysis patients, making it a more efficacious and effective treatment regimen compared with
HD.
35 HP has been reported to be safer and more feasible than other HD therapies when used to treat children, since the tubes and cartridge are all disposable and can eliminate inflammatory mediators efficiently.
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The efficacy and living quality in CRF patients following treatment were also assessed and the results showed that there was a great deal of improvement in the subjective feelings including fatigue, poor sleep, poor appetite, osteodynia, uremic pruritus, and neuropsychiatric disorders, an increase in the dry weight, and generally, patients had a better-quality life. The use of high-flux membranes in HDF has been proven to be useful in delaying the long-term complications. 36 In addition to the scarce removal of uremic toxins and protein-bound molecules in low-flux dialysis, the prevalence of long-term complications and poor quality of life in CRF patients are evident; HP treatment leads to better overall survival of patients. 37 There was an increase in the protein expression of CD40 and CD80 and decrease in CD62P and P10 expressions according to our results. The outcome differs in different HD therapies, with more significant outcomes in HDF and HP than in HD. CRF is a chronic condition characterized by inflammation, and hypercoagulability, meaning patients will have increased levels of procoagulant and inflammatory markers. 38 In CRF patients that had undergone HD, a transient decrease in CD40L and CD62P was known as B7-1, is a transmembrane, which is stimulated by an interaction with allergens and irritants. 42 The maturation of DC induces the upregulation of CD80 expression. 43 P10 is known to be involved in the regulation of angiogenesis, inflammation, and vascular function, and elevated levels of P10 are associated with an adverse outcome in HD patients.
44
Overall, the findings from our study provided evidence supporting HDF and HP as superior treatment regimens for CRF compared to HD and that the expressions of CD40, CD80, CD62P, and P10 can be correlated with the therapeutic efficacy of HD and improved prognosis. However, due to the limitation of this study in the form of the potential process by which monocytes can be further differentiated into DCs, as well as the expression of activated markers in different groups of DCs, further studies are needed to elucidate the same. 
TA B L E 3 Comparisons of the complications after HD therapy in all groups
F I G U R E 5
The lowered expression of CD40 and CD80 and increased expression of CD62P and P10 are correlated with complications after HD therapy. HD, hemodialysis; HDF, hemodiafiltration; HP, hemoperfusion; *, P < 0.05 vs the complicated group 
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